Liven Pharma Limited said it will raise Rs. 200 million via a rights issue to strengthen its financial position and fund expansion.
The company disclosed to the Pakistan Stock Exchange that it will issue 20 million ordinary shares at Rs. 10 each, representing about 21.5% of its paid-up capital. Shareholders will receive 21.496 rights shares for every 100 ordinary shares held.
Liven Pharma said proceeds will be used to support working capital, capital expenditures, and new investments, including a Dry Powder Injectables division, vehicle procurement, and costs related to Drug Regulatory Authority of Pakistan registration and licensing.
The company noted the issue price is set at face value, in line with prevailing market practice, and said substantial shareholders and directors have confirmed participation.
According to the disclosure, the rights issue is expected to improve profitability and shareholder returns while posing minimal investment risk, as the price is below the current market level.
The principal activity of the company is the manufacturing of pharmaceuticals and allied products.
Stay Connected with ProPakistani
Get the latest business news, market insights, and economic updates wherever you prefer.
Add ProPakistani to Preferred Sources and see more of our stories in Google Search and Top Stories.
PHARMA PRODUCTS ARE ALREADY SOLD AT HIGH PRICES AND NOT AFFORDABLE FOR THE COMMONS IN THE SOCIETY.IF THESE PRICES ARE EVEN MET WITH ARTICLE 38 OF THE CONSTITUTION EVEN THEN ARE NOT JUSTIFIED AND NOT AFFORDABLE FOR THE POOR AND THE COMMONS AND THE CONCERNED MINISTRIES AND THEIR SUPPORTING INSTITUTIONS MUST HAVE A DIALOGUE WITH BUT IT LOOKS THE PHARMA COMPANIES ARE ALMOST FREED TO DO WHAT THEY CONSIDER FOR THEIR COMPANIES BEST AND NOT BEST FOR THE COMMONS THAT WHAT AND WHY THE OTHER PHARMACEUTICAL COMPANIES HAVE JUMPED IN THE SOCIETY AND NOW COMPETING THESE MINTING FACTORIES.